Results 11 to 20 of about 121,575 (281)

Integrated assessment of rifampicin-mediated induction of transporters and drug-metabolizing enzymes in a long-term human liver tissue chip system. [PDF]

Clin Pharmacol Ther
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Hartauer ME, Lanphier RM, Ohri S, Snyder J, Tiley JB, Fallon JK, Ho H, Cirit M, Rajan SAP, Brouwer KLR.   +9 more
europepmc   +2 more sources

Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature [PDF]

, 2021
Thrombocytopenia may be associated with a variety of conditions and risks depending on its severity, ranging from mild epistaxis to life-threating bleeding. Many drugs or herbal remedies can cause thrombocytopenia by either inhibiting platelet production
Eleftheria Hatzimichael, Anastasia Serpanou, Eleni Kapsali, Konstantina Papathanasiou, Ioannis Papakonstantinou, Epameinondas Koumpis, Iliana Tassi   +6 more
core   +1 more source

The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus

Antibiotics, 2022
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S.
Jan Balansky, Kenneth Pfarr, Christiane Szekat, Stefan Kehraus, Tilman Aden, Miriam Grosse, Rolf Jansen, Thomas Hesterkamp, Andrea Schiefer, Gabriele M. König, Marc Stadler, Achim Hoerauf, Gabriele Bierbaum   +12 more
doaj   +1 more source

Rifampicin resistance in tuberculosis outbreak, London, England [PDF]

, 2005
Mycobacterium tuberculosis isolates cultured from 6 patients associated with an isoniazid-resistant M. tuberculosis outbreak acquired rifampicin resistance. The rpoB gene sequence showed that resistance was associated with rare mutations in each isolate.
Shorten, R J, McHugh, TD, Claxton, A P, Claxton, AP, Mary Jo Knobloch, Gillespie, S H, Claire Jenkins, Stephen H. Gillespie, Shorten, RJ, McHugh, T D, Edward A. Belongia, Richard E. Besser, Timothy D. McHugh, Robert J. Shorten, Burney A. Kieke, Carolyn Janette, Gillespie, SH, Jeffrey P. Davis, Jenkins, C, Alleyna P. Claxton   +19 more
core   +1 more source

Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. [PDF]

, 2007
BACKGROUND: Resistance to anti-tuberculosis drugs is a serious public health problem. Multi-drug resistant tuberculosis (MDR-TB), defined as resistance to at least rifampicin and isoniazid, has been reported in all regions of the world.
Traore, Hamidou, Hamidou Traore, Jones-Lopez, Edward C, McNerney, Ruth, Eisenach Kathleen D, Joloba, Moses L, Jones-Lopez Edward C, Roy D Mugerwa, Smith, Peter G, Mugerwa, Roy D, Ogwang Sam, Smith Peter G, Moses L Joloba, Mallard, Kim, Kathleen D Eisenach, Jerrold J Ellner, Ellner, Jerrold J, Eisenach, Kathleen D, Ogwang, Sam, Mugerwa Roy D, Kayes, Susan, McNerney Ruth, Edward C Jones-Lopez, Kalpana Narayan, Ruth McNerney, Peter G Smith, Sam Ogwang, Susan Kayes, Joloba Moses L, Narayan, Kalpana, Francis Mumbowa, Narayan Kalpana, Ellner Jerrold J, Mumbowa, Francis, Kayes Susan, Kim Mallard, Traore Hamidou, Mumbowa Francis, Mallard Kim   +38 more
core   +1 more source

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy [PDF]

, 2016
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after ...
Richard Anthony, Steinmann, P. (Peter), Mieras, Liesbeth, Bratschi, M W, Jan Hendrik Richardus, Kasang, C. (Christa), Arielle Cavaliero, Mieras, L. (Liesbeth), Lee Reichman, Jacques van den Broek, Cavaliero, A. (Arielle), Christa Kasang, Yew, W.W. (Wing Wai), Anthony, R, van Brakel, Wim, Reichman, L, Emmanuelle Cambau, Anthony, Richard, Steinmann, Peter, Perera, G, Saunderson, P. (Paul), Saunderson, Paul, Cavaliero, Arielle, Saunderson, P, Richardus, Jan hendrik; id_orcid, Kasang, Christa, van den Broek, Jacques, Kasang, C, Richardus, J.H. (Jan Hendrik), Cavaliero, A, Cambau, E. (Emmanuelle), Peter Steinmann, Anthony, R. (Richard), Yew, W W, Reichman, L. (Lee), Mieras, L, Yew, Wing Wai, Perera, G. (Geethal), Richardus, Jan Hendrik, Wim van Brakel, Brakel, W.H. (Wim) van, Bratschi, M.W. (Martin W.), Paul Saunderson, van Brakel, W, Cambau, E, Reichman, Lee, van den Broek, J, Bratschi, Martin W., Steinmann, P, Cambau, Emmanuelle, Geethal Perera, Wing Wai Yew, van den Broek, J. (Jacques), Perera, Geethal, Liesbeth Mieras, Martin W. Bratschi   +55 more
core   +2 more sources

Cell membrane components of Brucella melitensis play important roles in the resistance of low-level rifampicin.

PLoS Neglected Tropical Diseases, 2020
Brucella spp. are facultative intracellular pathogens that can persistently colonize host cells and cause the zoonosis- brucellosis. The WHO recommended a treatment for brucellosis that involves a combination of doxycycline, rifampicin, or streptomycin ...
Xiaowen Yang, Tonglei Wu, Wenxiao Liu, Guozhong Tian, Hongyan Zhao, Dongri Piao, Hai Jiang, Qingmin Wu   +7 more
doaj   +1 more source

AtriplaR/anti-TB Combination in TB/HIV Patients. Drug in Focus. [PDF]

, 2011
Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral
Semvua Hadija H, Kibiki, Gibson S, Hadija H Semvua, Gibson S Kibiki, Semvua, Hadija H, Kibiki Gibson S   +5 more
core   +1 more source

Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endograft infections [PDF]

, 2021
Background Optimal timing for rifampicin combination therapy in patients with staphylococcal vascular graft/endograft infection (S-VGEI) is unknown.
Zimmermann, Alexander, Zbinden, Reinhard, Leung, Yau Kei Stefan, Rancic, Zoran, Hasse, Barbara, Eberhard, Nadia, Zinkernagel, Annelies S; https://orcid.org/, Brugger, Silvio D; https://orcid.org/, Mestres, Carlos A, Ledergerber, Bruno   +9 more
core   +1 more source

High dose rifampicin kills persisters, shortens treatment duration and reduces relapse rate in vitro and in vivo

Frontiers in Microbiology, 2015
Although high-dose rifampicin holds promise for improving tuberculosis control by potentially shortening treatment duration, these effects attributed to eradication of persistent bacteria are unclear. The presence of persistent M.
Yanmin eHu, Alexander eLiu, Fatima eOrtega-Muro, Laura eAlameda-Martin, Denis eMitchison, Anthony eCoates   +5 more
doaj   +1 more source